Pan Cancer T announces that Dr. Helen Tayton-Martin has joined its board as an independent director
Dr. Helen Tayton-Martin joins our board, bringing decades of leadership in TCR-T cell therapy and biotech growth.
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
October 28, 2021
ROTTERDAM, October 28, 2021 – Pan Cancer T B.V., a biotech spin-off from the Erasmus MC dedicated to the discovery and development of novel TCR-T therapies against solid tumors, announced today the closing of an extended seed investment round. All current shareholders participated in the round, with Thuja Capital joining as a new investor. The undisclosed proceeds add to the initial seed capital financing announced earlier this year. The Company’s syndicate of experienced life science venture capital investors now includes Van Herk Ventures, Swanbridge Capital, and Thuja Capital as well as founding shareholder Erasmus MC.
Katrien Reynders-Frederix, CEO of Pan Cancer T, said: “Despite certain successes of adoptive cell therapies like the Chimeric Antigen Receptor (CAR) T cell therapy, the vast majority of solid cancers remains refractory to such treatments. TCR-T cell therapy is a novel, promising option that has demonstrated significant clinical benefits in patients with various solid tumors. Thanks to the extended seed round and the continuous support of our investors we will be able to further advance our lead program and strengthen our pre-clinical assets. Next, we will be preparing to raise a Series A financing round to advance our lead program into the clinic.”
Michel Briejer, Investment Manager at Thuja Capital added: “Since we identified Pan Cancer T as an investment opportunity, we have been deeply impressed by the quality of the science, the team and its advisers. We are thrilled to join the shareholder base and take a seat on the Supervisory Board to help and support Pan Cancer T towards the success it is bound for.”
Dharminder Chahal, Investment Manager at Van Herk and Swanbridge Capital, said: “I am pleased to see that Pan Cancer T made such a progress within only one year after its foundation. I am convinced that the company will continue this high pace of development through this additional investment.”
Prof. Chris Bangma, Professor of the Department of Urology at Erasmus University Medical Centre in Rotterdam, stated: “Erasmus MC valorizes the development of novel therapeutic treatment options for its patients. The results of immune therapy in various tumors are beyond expectations. Many patients may benefit from the carefully designed new immunologic approaches and evaluation in the clinic. Hence, Erasmus MC is pleased to support Pan Cancer T on this journey.”
Other news
Pan Cancer T’s potential recognised at MEET2WIN with two awards
Pan Cancer T’s strong investment potential was highlighted at MEET2WIN with two awards, giving CEO Rachel Abbott a platform to present in depth and receive direct feedback from leading European oncology experts and top pharma companies.
Extended Partnership with NecstGen
Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have agreed to...
4.25 Million in Seed Extension Round
Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round.
Pan Cancer T are EIT Health Catapult Finalists
On 5th June, our CEO, Rachel Abbott, was pleased to represent Pan Cancer T in the EIT Health Catapult finals at the health.tech global summit in Munich.
Awarded the Seal of Excellence from the European Commission
Amongst a record number of applicants, Pan Cancer T’s EIC Accelerator proposal has been awarded the Seal of Excellence.
Selected as semi finalist of the EIT Health Catapult venture challenge
Pan Cancer T has been selected as semi finalist of the EIT Health Catapult venture challenge
Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Poster Presentation
Pan Cancer T is presenting preclinical data at CIMT and SITC 2023
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
“I am excited to join Pan Cancer T´s Scientific Advisory Board,” said Prof. Dr. Chiara Bonini. “T cell therapies hold tremendous promises for tumor patients and the development of TCR T therapies is just gaining momentum. I am convinced that Pan Cancer T will play a pioneering role in this field, as the Company is working on the main challenges in the field: identifying novel tumor antigens and leveraging engineering technology to enhance the T cells´ durability.”